Evolva has posted its financial results for the period from 1 January to 31 December 2018. Product sales reached CHF 3.4 million in 2018 (+70%); overall revenues were CHF 8.9 million (+31%).

The company says it is on track to reach cash break-even in the 2021/23 timeframe.

Evolva CEO Oliver Walker said: “Evolva achieved substantial progress across the board in 2018. We have put our house in order, adding a clear customer focus on top of our strong basis in research and development. We have at the same time improved our financial profile, paving a more solid road towards profitability. We are excited about our prospects going into 2019. We expect a growth acceleration for the EverSweet product and a US registration for nootkatone in pest control. These milestones will enhance the opportunities to unlock significant additional income streams for Evolva. And, last but not least, we have several new products in late stage development which could potentially go to market in the foreseeable future.”